📊 CTRVP Key Takeaways
Is Hepion Pharmaceuticals, Inc. (CTRVP) a Good Investment?
Hepion Pharmaceuticals is a pre-revenue pharmaceutical company with severe operational losses and negative profitability metrics, burning cash at an unsustainable rate despite holding adequate liquidity. The company lacks revenue generation capability while incurring significant operating expenses, resulting in negative ROE of -310% and operating cash flow burn of -3.3M annually. Without demonstrated clinical progress, revenue generation, or clear path to profitability, the company represents extremely high risk.
Hepion Pharmaceuticals shows the classic profile of a distressed pre-revenue biotech: no revenue base, persistent operating and free cash flow losses, and a cash balance that appears insufficient to fund even one year of recent burn. While leverage is low and current liquidity looks strong on paper, the fundamental issue is weak business viability without a clear path to commercialization, partnership income, or major external financing.
Why Buy Hepion Pharmaceuticals, Inc. Stock? CTRVP Key Strengths
- Strong liquidity position with 10.25x current ratio and $1.8M cash reserves relative to $3.1M total assets
- Minimal debt burden with debt-to-equity ratio of only 0.07x, reducing financial distress risk
- Low absolute liabilities at $402.4K provide operational flexibility
- Low balance-sheet leverage with debt/equity of just 0.07x
- High current and quick ratios indicate limited near-term balance-sheet pressure
- Net loss improved year over year, suggesting some expense reduction
CTRVP Stock Risks: Hepion Pharmaceuticals, Inc. Investment Risks
- Complete absence of revenue ($0.00) indicates pre-commercial stage with unproven business model
- Severe cash burn of -$3.3M in operating activities will deplete available cash within 7 months at current burn rate
- Catastrophic profitability metrics including -310% ROE, -269% ROA, and -$8.3M net loss demonstrate inability to generate value
- No insider buying activity in last 90 days suggests lack of confidence from management
- Operating losses of -$4.2M with zero offsetting revenue indicates excessive operating expenses relative to stage
- Zero revenue means the business is entirely dependent on external funding rather than operations
- Cash burn is severe, with operating cash flow of -$3.27M against only $1.83M of cash
- Very weak profitability metrics, including negative ROE and ROA, point to poor capital efficiency
Key Metrics to Watch
- Clinical trial progress and regulatory milestones toward revenue-generating assets
- Monthly operating cash burn rate and runway until capital depletion
- Achievement of first revenue milestone or partnership announcement
- Quarterly cash burn relative to cash on hand
- Any emergence of recurring revenue, licensing income, or clinical/commercial milestone payments
Hepion Pharmaceuticals, Inc. (CTRVP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.25x current ratio provides a solid financial cushion.
CTRVP Profit Margin, ROE & Profitability Analysis
CTRVP vs Healthcare Sector: How Hepion Pharmaceuticals, Inc. Compares
How Hepion Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hepion Pharmaceuticals, Inc. Stock Overvalued? CTRVP Valuation Analysis 2026
Based on fundamental analysis, Hepion Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hepion Pharmaceuticals, Inc. Balance Sheet: CTRVP Debt, Cash & Liquidity
CTRVP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hepion Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-107.35 indicates the company is currently unprofitable.
CTRVP Revenue Growth, EPS Growth & YoY Performance
CTRVP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | N/A | -$2.9M | $-0.56 |
| Q3 2023 | N/A | -$6.9M | $-2.24 |
| Q2 2023 | N/A | -$6.9M | $-3.68 |
| Q1 2023 | N/A | -$6.9M | $-1.82 |
| Q3 2022 | N/A | -$6.1M | $-0.11 |
| Q2 2022 | N/A | -$6.1M | $-0.10 |
| Q1 2022 | N/A | -$6.1M | $-0.09 |
| Q3 2021 | N/A | -$4.2M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hepion Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CTRVP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hepion Pharmaceuticals, Inc. (CIK: 0001583771)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTRVP
What is the AI rating for CTRVP?
Hepion Pharmaceuticals, Inc. (CTRVP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTRVP's key strengths?
Claude: Strong liquidity position with 10.25x current ratio and $1.8M cash reserves relative to $3.1M total assets. Minimal debt burden with debt-to-equity ratio of only 0.07x, reducing financial distress risk. ChatGPT: Low balance-sheet leverage with debt/equity of just 0.07x. High current and quick ratios indicate limited near-term balance-sheet pressure.
What are the risks of investing in CTRVP?
Claude: Complete absence of revenue ($0.00) indicates pre-commercial stage with unproven business model. Severe cash burn of -$3.3M in operating activities will deplete available cash within 7 months at current burn rate. ChatGPT: Zero revenue means the business is entirely dependent on external funding rather than operations. Cash burn is severe, with operating cash flow of -$3.27M against only $1.83M of cash.
What is CTRVP's revenue and growth?
Hepion Pharmaceuticals, Inc. reported revenue of $0.0.
Does CTRVP pay dividends?
Hepion Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CTRVP SEC filings?
Official SEC filings for Hepion Pharmaceuticals, Inc. (CIK: 0001583771) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTRVP's EPS?
Hepion Pharmaceuticals, Inc. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTRVP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hepion Pharmaceuticals, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTRVP stock overvalued or undervalued?
Valuation metrics for CTRVP: ROE of -310.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CTRVP stock in 2026?
Our dual AI analysis gives Hepion Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTRVP's free cash flow?
Hepion Pharmaceuticals, Inc.'s operating cash flow is $-3.3M, with capital expenditures of $14.3K.
How does CTRVP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -310.3% (avg: 15%), current ratio 10.25 (avg: 2).